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Strengths and limitations of this study
 ► Real-life patient cohort of over-the-counter 
short-acting beta agonist users obtained in commu-
nity pharmacy.
 ► Use of validated tools allowed for comparison with 
other studies.
 ► Patient diagnosis of asthma and healthcare utilisa-
tion could not be confirmed objectively.
AbStrACt
Objectives Overuse of asthma relievers is associated 
with significant adverse consequences. This study aimed 
to better understand the population purchasing and 
using short-acting beta agonists (SABA) over the counter 
(OTC); and compare the demographic, clinical and 
behavioural characteristics of those who overuse SABA 
with those who do not.
Design and setting Real-world cross-sectional 
observational study in community pharmacy.
Participants Of 412 participants ≥16 years requesting 
SABA OTC, 289 were SABA overusers (used SABA more 
than twice per week in the past 4 weeks).
Main outcome measure Reliever use, Global Initiative for 
Asthma-defined control, healthcare utilisation, patterns of 
preventer use.
results 70.1% of participants were classified as 
SABA overusers, that is, reporting SABA use more than 
twice a week within the last 4 weeks, 73.6% reported 
not using a preventer daily and only 81.6% reported a 
doctor diagnosis of asthma. SABA overusers were more 
likely to have moderate-severe nasal symptoms (80.8% 
vs 63.0%, p<0.001) and a diagnosis of depression 
(11.1% vs 5.7%, p<0.001), when compared with SABA 
non-overusers. A higher proportion of SABA overusers 
had uncontrolled asthma (59.0% vs 15.4%, p<0.001), 
were more likely to use oral corticosteroids to manage 
worsening asthma symptoms (26.2% vs 13.5%, p<0.01) 
and visit the doctor for their asthma in the past 12 
months (74.5% vs 62.5%, p<0.01), when compared to 
SABA non-overusers.
Conclusions This study uncovers a hidden population 
of people who can only be identified in pharmacy with 
suboptimal asthma, coexisting rhinitis, poor preventer 
adherence and, in some cases, no asthma diagnosis.
IntrODuCtIOn
Asthma currently affects an estimated 
385 million individuals worldwide.1 2 
Despite advances in disease understanding, 
the development of asthma management 
guidelines and the availability of effective 
treatment,2–5 poor asthma control remains 
a major problem with approximately 50% of 
people living with suboptimally controlled 
disease.6 7 Poor asthma control is associated 
with an increased risk of exacerbations, 
poor quality of life, reduced productivity 
for individuals and increased healthcare 
utilisation.7 8 Common risk factors for poor 
asthma control include suboptimal medica-
tion use including poor inhaler technique, 
suboptimal adherence, reliever overuse, 
as well as poorly controlled comorbidi-
ties such as rhinitis.9 These risk factors or 
modifiable elements that impact symptoms 
and prognosis can be successfully targeted 
with optimal treatment to improve disease 
control.10 Therefore, the identification of 
these factors is critical.
Inhaled medications are the cornerstone 
of pharmacological treatment of asthma, 
and are a fundamental element of disease 
management and self-management. Due 
to the nature of the medications and the 
important distinction in which medica-
tions are used to treat asthma (ie, reliever 
vs preventer treatments), patients’ self-man-
agement with their medications can give us 
insights into both disease status and modifi-
able factors.
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Research has identified that inappropriate use 
of asthma medications is a significant issue from a 
global perspective, with the overuse of reliever medi-
cations and underuse of preventer medications.11–13 
For example, in the USA a medical expenditure panel 
survey found that 15% of the asthmatic population in 
the USA overuse short-acting beta agonists (SABA)13 
and 25% of patients used relievers as a monotherapy to 
manage their persistent asthma symptoms, that is, failed 
to use a preventer medication.14
In asthma, the inappropriate use of medications 
has significant adverse consequences.15 Overuse of 
SABA therapy is associated with poor asthma control,16 
increased airway hyper-responsiveness,17 increased asth-
ma-related mortality18 and increased healthcare utilisa-
tion due to asthma.19 Excessive use of SABA medication 
has been associated with epidemics of asthma deaths, 
and dispensing of more than 12 SABA inhalers to one 
individual over a 12-month period is associated with 
increased risk of asthma-related death.20 It is therefore 
critical and a fundamental principle of asthma medi-
cation management that, as the guidelines articulate, 
SABA use be exclusively restricted to use on an ‘as 
needed’ basis.21
One healthcare environment, which can provide a 
unique perspective on the use of asthma medications, 
is the community pharmacy. Community pharmacy 
provides an opportunity to explore people with asthma 
based on their medication purchasing behaviour and 
to provide insights into the way in which they more 
broadly use their asthma medicines. Patients access 
pharmacies worldwide to purchase medications, where 
they determine which medication to purchase, whether 
it be a reliever medication or preventer. The Australian 
context provides us with a unique opportunity, that 
is, it enables us to explore the true self-management 
behaviours of people with asthma, through the use of 
SABA medicines, within a less restricted prescribing 
environment. In Australia, SABA medication can be 
purchased in community pharmacy directly from a 
pharmacist over the counter (OTC) without the need 
for a prescription. While a minority of patients will 
purchase an SABA with a prescription, more than 60% 
of SABA purchases are made OTC.22 Research has 
confirmed that OTC supply of SABA has been linked 
to undertreatment of asthma22 and this is of particular 
importance as SABA medications are often used by 
patients without regular medical supervision.23 There-
fore, making it a truly unique environment, that in an 
abundance of healthcare availabilities, patients are still 
overusing SABA for symptom relief. The implications of 
such research are of value and relevance globally.
Therefore, the specific objectives of this study were 
to describe the use of SABA in the Australian commu-
nity pharmacy setting, and to identify and compare the 
demographic, clinical and behavioural characteristics 
of people with asthma who overuse SABA compared 
with those who do not.
MethODS
Study design
This study took the form of a real-world cross-sectional 
observational study conducted on a sample of phar-
macy customers purchasing OTC SABA medication 
from community pharmacies between October 2017 and 
October 2018. No prior assumptions of asthma history 
were made, but focused on patient behaviour, that is, 
SABA purchase.
Pharmacists employed in different community pharma-
cies across various geographical and sociodemographic 
regions of New South Wales who had previously expressed 
an interest in being involved in research were invited to 
participate. In total, pharmacists across 18 different phar-
macies invited customers to complete a structured survey 
following the purchase of SABA medication. The phar-
macist distributed the patient survey in their pharmacy 
within their usual course of working hours. No funding 
was available and pharmacists’ efforts were voluntary.
Pharmacy customers were invited to participate if they 
fulfilled the following inclusion criteria: individuals aged 
16 years and over, purchased OTC SABA medication for 
themselves from community pharmacy and were able 
to communicate in English. All participants provided 
informed consent. There were no exclusion criteria to 
participation.
Data were collected using a structured self-administered 
questionnaire (online supplementary appendix 1), which 
took approximately 15 min to complete in the pharmacy 
setting. The questionnaire was divided into two sections 
and captured data relating to patient demographics 
and clinical characteristics, asthma symptoms, rhinitis 
symptoms, action plan ownership, SABA use, medica-
tion adherence, attitudes towards asthma and asthma 
medications, medication side effects, inhaler device use, 
occurrence of exacerbations and healthcare utilisation 
(online supplementary appendix 1). The questionnaire 
was developed based on empirical evidence and quantita-
tive research, and collected domains relating to treatable 
traits of airway diseases.6 7 10 24
Participants who were not diagnosed with asthma were 
excluded from answering the second part of the ques-
tionnaire, that is, asthma-specific questions concerning 
asthma control, healthcare utilisation and preventer 
medication usage, as the structure of the questionnaire 
prompted them to stop at the asthma-specific questions 
(online supplementary appendix 1).
Participants were asked in the ‘last week how many times 
they used their reliever’ medication, and categorised as 
overusing their SABA if ‘Three or more times a week’ 
was selected. Participant responses were cross-checked 
against the Global Initiative for Asthma (GINA) criteria, 
‘reliever needed for symptoms more than twice a week’, 
participants were categorised into two groups based on 
the reported frequency of SABA use for symptom relief in 
the past 4 weeks into SABA overuse (more than twice per 
week in the past 4 weeks) and no SABA overuse (less than 
twice per week in the past 4 weeks).2
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Patterns of preventer medication use were evalu-
ated with a single question adapted from the Recognise 
Asthma and Link to Symptoms and Experience study,6 25 26 
in which participants were asked to select a statement 
that best described how they take their preventer therapy. 
Participants were able to make multiple selections identi-
fying the reasons for suboptimal adherence as per Price 
et al.25
Asthma control was assessed using GINA-defined 
control; asthma status was labelled as controlled, partially 
controlled or uncontrolled depending on selected 
responses.2
Healthcare utilisation was identified by the following 
patient-reported outcomes: hospital admission or emer-
gency attendance related to asthma, and a visit to the 
physician due to asthma in the last 12 months.
Asthma exacerbations were identified by patients’ use 
of a course of oral steroids for worsening asthma in the 
last 12 months.
Self-reported rhinitis symptoms were assessed with a 
two-part question derived from the Allergic Rhinitis and 
Its Impact on Asthma and the International Primary 
Care Respiratory Group definition of rhinitis,27 28 as per 
Bosnic-Anticevich et al.24
The questionnaire was designed to facilitate quick and 
easy self-administration and reviewed by an expert panel 
of clinical pharmacists, general practitioners and respi-
ratory specialists. All responses were anonymised and 
participants were deidentified.
Data analysis
Data were analysed using SPSS V.23 (SPSS-IBM). 
Descriptive statistics were used to summarise patient 
characteristics.
Based on a 2015 survey stating that 2.5 million people 
in Australia are living with asthma,29 the minimum sample 
size would be 385 responses, to give a confidence level of 
95% with a 5% margin of error with an SD of 0.5.
Data were compared between participants who overused 
SABA medication and those who did not. Continuous 
variables that were normally distributed were compared 
using Student’s t-test, and the Mann-Whitney U test was 
used for continuous variables that were not normally 
distributed. Categorical variables were compared using 
Pearson χ2 test. A significance level of p<0.05 was used for 
all statistical procedures.
Patient and public involvement
This research was conducted without patient input in the 
study design, patient-relevant outcomes or result interpre-
tation. Patients were asked to complete the questionnaire 
which was based on current global asthma management 
guidelines and published patient data.
reSultS
A total of 412 SABA users completed the questionnaire, 
of whom 81.6% (336/412) reported a doctor diagnosis of 
asthma and 70.1% (n=289/412) were classified as SABA 
overusers, that is, reporting SABA use more than twice 
a week in the last 4 weeks. Patient demographics are 
summarised in table 1. SABA overusers were more likely 
to be older, have an asthma diagnosis and have a posi-
tive smoking history than SABA non-overusers (table 1). 
SABA overusers were also more likely to have a coexisting 
diagnosis of depression than non-overusers (11.1% vs 
5.7%, p<0.001) (table 1).
reported history of asthma
Not all participants reported an asthma diagnosis 
(n=76/412 (18.4%)). SABA overusers were more likely to 
report having a doctor diagnosis of asthma than SABA 
non-overusers (85.8% vs 71.5%, p<0.001) (table 1). 
Sixteen participants (n=16/412 (3.9%)) were unsure of 
whether they had an asthma diagnosis: all of these partici-
pants reported having no lung function testing.
Of the 336 participants who reported a doctor diag-
nosis of asthma, 61.9% (n=208/336) reported having 
their diagnosis confirmed with a lung function test. A 
subset of participants (n=18/314 (6%)) self-diagnosed 
themselves to have asthma without healthcare profes-
sional (HCP) confirmation. Twelve per cent (n=40/336) 
of participants who reported having a doctor diagnosis of 
asthma rejected their asthma diagnosis (table 1).
reliever medication use
The majority of participants (99%) were recommended 
SABA by a physician, 92.7% (382/412) were using 
SABA via a pressurised metered-dose inhaler and 36.9% 
(189/412) reported using more than four puffs of SABA 
a day over the previous 4 weeks. A smaller proportion 
of SABA overusers compared with SABA non-overusers 
reported a positive response to ‘I only use my SABA when 
symptoms are present’ (60.6% vs 82.1%, respectively, 
p<0.001) (table 2).
SABA overusers were more likely to report to have 
taken a maximum number of five or more puffs of SABA 
in 1 day in the previous 4 weeks compared with SABA 
non-overusers (46.0% vs 15.4%, p<0.001) (table 2). Addi-
tionally, SABA overusers owned a significantly greater 
number of SABA inhalers at any one time compared with 
SABA non-overusers (table 2).
Overall, 39.6% (n=163/412) of participants reported 
experiencing an SABA-associated side effect, with a 
higher proportion of SABA overusers experiencing side 
effects compared with SABA non-overusers (43.3% vs 
30.9%, p<0.001) (table 2). The most commonly experi-
enced side effect was dry mouth (table 2).
rhinitis symptoms
Overall, 59.7% (n=246/412) of participants reported a 
diagnosis of comorbid allergic rhinitis (AR); however, 
70.9% (n=292/412) of participants reported experiencing 
nasal symptoms (itchy, runny, blocked nose or sneezing 
when they do not have a cold), independent of whether 
they had a diagnosis or not. Of participants who reported 
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Table 1 Patient demographics, asthma diagnosis, smoking status and comorbidities
Overall
n=412
SABA overuse
No
n=123
Yes
n=289 P value
Female, n (%) 216 (52.4) 73 (59.3) 143 (49.5) 0.066
Age (years), mean (SD) 43 (17.89) 39 (18.02) 44 (17.59) <0.001
Age range (years), n (%)
  16–29 113 (27.4) 45 (36.6) 68 (23.5) 0.023
  30–49 147 (35.7) 40 (32.5) 107 (37)
  50 or more 152 (36.9) 38 (30.9) 114 (39.4)
Asthma diagnosis, n (%)
  Physician-diagnosed asthma (self-report) 336 (81.6) 88 (71.5) 248 (85.8) <0.001
  Patient perceives they have asthma 314 (76.2) 71 (57.7) 243 (84.1) <0.001
Comorbidities, n (%)
  Rhinitis 246 (59.7) 66 (53.7) 180 (62.3) 0.102
  Eczema 80 (19.4) 23 (18.7) 57 (19.7) 0.810
  Gastro-oesophageal reflux disease 69 (16.7) 16 (13) 53 (18.3) 0.185
  Hypertension 69 (16.7) 14 (11.4) 55 (19) 0.128
  Depression 44 (10.7) 7 (5.7) 37 (11.1) 0.032
  Obstructive sleep apnoea 39 (9.5) 10 (8.1) 29 (10) 0.546
  Chronic obstructive pulmonary disease 41 (10) 8 (6.5) 33 (11.4) 0.127
Smoking history, n (%)
  Never smoked 271 (65.8) 93 (75.6) 178 (61.6) 0.021
  Past smoker 99 (24.1) 20 (16.3) 79 (27.3)
  Current smoker 42 (10.2) 10 (8) 32 (11)
SEIFA, n (%)
  1 (most advantaged) 67 (16.3) 24 (19.5) 43 (14.9) 0.644
  2 73 (17.7) 20 (16.3) 53 (18.3)
  3 88 (21.4) 22 (17.9) 66 (22.8)
  4 72 (17.5) 23 (18.7) 49 (17)
  5 (most disadvantaged) 112 (27.2) 34 (27.6) 78 (27)
SABA, short-acting beta agonist; SEIFA, Socio-Economic Indexes for Areas quintiles.
experiencing rhinitis symptoms, 24.0% (70/292) were 
classified as having mild rhinitis and 76.0% (222/292) 
had moderate-severe rhinitis symptoms. In participants 
reporting nasal symptoms, a significantly higher propor-
tion of SABA overusers reported moderate-severe nasal 
symptoms compared with SABA non-overusers (80.8% vs 
63.3%, p<0.001) (figure 1A,B).
Asthma symptom control and healthcare utilisation
Participants without a doctor diagnosis of asthma were 
prompted to stop after section 1 of the questionnaire 
at asthma-specific questions (due to the structure of the 
questionnaire); 39 participants who were unsure of their 
asthma diagnosis continued to complete the question-
naire. Missing responses are excluded from this part of 
the analysis (37/412 (9.0%)).
Based on GINA-defined criteria, overall, 17.6% 
(n=66/375), 35.5% (n=133/375) and 46.9% (n=176/375) 
of participants had controlled, partially controlled 
and uncontrolled asthma, respectively (table 3); with a 
higher proportion of SABA overusers with uncontrolled 
asthma (59.0% vs 15.4%, p<0.001) compared with SABA 
non-overusers. SABA non-overusers were more likely to 
have well-controlled asthma compared with SABA over-
users (48.1% vs 5.9%, p<0.001) (table 3).
Table 3 summarises the proportion of participants 
presenting to emergency, being hospitalised and using 
oral steroids for their asthma, in the last 12 months. In 
the year prior to the survey, 22.7% (n=85/375) reported 
having used at least one short-term course of oral steroids 
for asthma (table 3). SABA overusers were more likely 
to use oral corticosteroids to manage worsening asthma 
symptoms within the last 12 months (26.2% vs 13.5%, 
p<0.01), and a visit to the doctor for asthma (74.5% vs 
62.5%, p<0.01) than SABA non-overusers (table 3).
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Table 2 Short-acting beta agonist (SABA) medication use overall and by SABA overuse versus SABA non-overuse (n=412)
SABA medication use
Overall
n=412
   SABA overuse
No
n=123
Yes
n=289 P value
SABA device, n (%)
  pMDI 307 (74.5) 98 (79.7) 209 (72.3) 0.363
  pMDI and spacer 75 (18.2) 18 (14.6) 57 (19.7)
  Turbuhaler 28 (6.8) 6 (4.9) 22 (7.6)
  Autohaler 2 (0.5) 1 (0.8) 1 (0.3)
Maximum number of SABA puffs in 1 day*, n (%)
  1–4 260 (63.1) 104 (84.6) 156 (54) <0.001
  5–12 128 (31.1) 17 (13.8) 111 (38.4)
  >12 24 (5.8) 2 (1.6) 22 (7.6)
SABA used only when symptoms present, n (%)
  ‘Yes’ response 276 (67) 101 (82.1) 175 (60.6) <0.001
SABA side effects experienced, n (%)
  163 (39.6) 38 (30.9) 125 (43.3) 0.019
  Dry mouth 67 (16.3) 16 (13) 51 (17.6)
  Palpitations 34 (8.3) 7 (5.7) 27 (9.3)
  Tremor 26 (6.3) 10 (8.1) 16 (5.5)
  Chest tightness 12 (3) 6 (4.9) 6 (2.1)
  Muscle cramps 8 (2) 3 (2.4) 5 (1.7)
  Headache 18 (4.4) 8 (6.5) 10 (3.5)
SABA inhalers at any one time, 
n (SD)
2.22 (±) 1.116 1.86 (±) 0.917 2.37 (±) 1.16 <0.001
*Maximum number of puffs used in 1 day in the last 4 weeks.
pMDI, pressurised metered-dose inhaler.
Preventer medication use
Overall, 68.0% (n=255/375) of participants reported 
currently having a preventer medication, 29.9% 
(n=112/375) and 57.1% (n=214/375) reported being 
instructed to use a preventer when required and every 
day, respectively, while 73.6% (n=276/375) reported not 
using a preventer every day. A significantly lower propor-
tion of SABA overusers reported being instructed to use 
their preventer medication every day compared with 
SABA non-overusers (41.0% vs 63.0%, p<0.01) (table 4); 
however, there was no significant difference between the 
two groups with regard to reported daily use (table 4).
Overall, 25.9% (n=97/375) of participants used their 
preventer on an ‘as needed’ basis. The most common 
reasons reported by participants for not using a preventer 
medication every day was the belief that they ‘did not need’ 
to use their preventer (62.4% (n=234/375)), followed 
by the presence of side effects (18.1%, n=68/375) and 
the belief that the preventer ‘does not work’ (13.3%, 
n=50/375). There were significant differences between 
SABA overusers and SABA non-overusers with regard to 
some of the reasons behind not taking preventer medica-
tion every day (table 4).
DISCuSSIOn
This study provided a unique ‘snapshot’ of SABA reliever 
users presenting to Australian community pharmacies 
and their current asthma status. Several key findings were 
identified: (1) not all individuals who purchase an SABA 
acknowledge that they have an asthma diagnosis; (2) 
SABA overuse is extremely high, while preventer medica-
tion use remains low; (3) Approximately a quarter of indi-
viduals in the community experience ‘controlled asthma’; 
(4) SABA overusers are more likely to have moderate-se-
vere rhinitis symptoms; and (5) SABA overusers are more 
likely to have used a course of oral corticosteroids in the 
previous 12 months. Addressing these key findings in 
primary care is crucial to reduce the risk of asthma exac-
erbations and optimise asthma control.
This study revealed that a high proportion of partici-
pants overused SABA medication. Just over two-thirds 
of participants were using their SABA medication more 
than twice a week, this is a significant problem and 
factors warranting this overuse need to be identified 
and treated. In this study, participants were also asked 
about the maximum number of doses of SABA admin-
istered in 1 day in the past month, revealing that more 
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Figures 1a and 1b: Incidence of mild and moderate-severe rhinitis symptoms among Short Acting Beta 
Agonist (SABA) non-over users and over users. 
+Mild Rhinitis (n=70) classified if participants experienced symptoms and symptoms were not bothersome.  
++Moderate-Severe Rhinitis (n=222) classified if participants experienced symptoms and symptoms were 
bothersome. 
 
34%
25%
41%
a) SABA Non-overuse
26%
14%
60%
b) SABA Overuse
No Rhinitis
Symptoms
Mild Rhinitis
Moderate-Severe
Rhinitis
Figure 1 (A, B) Incidence of mild and moderate-severe rhinitis symptoms among short-acting beta agonist (SABA) non-
overusers and overusers. Mild rhinitis (n=70) classified if participants experienced symptoms and symptoms were not 
bothersome. Moderate-severe rhinitis (n=222) classified if participants experienced symptoms and symptoms were bothersome.
Table 3 Asthma control, indicators of acute exacerbations and healthcare utilisation overall and by short-acting beta agonist 
(SABA) overuse versus non-overuse (n=375)
Asthma control
Overall
n=375
SABA overuse
No
n=104
Yes
n=271 P value
Asthma symptom control (GINA-defined)
  Well controlled 66 (17.6) 50 (48.1) 16 (5.9) <0.001
  Partly controlled 133 (35.5) 38 (36.5) 95 (35.1)
  Uncontrolled 176 (46.9) 16 (15.4) 160 (59)
Acute exacerbations*
  Oral steroid use for worsening asthma
  ≥1 85 (22.7) 14 (13.5) 71 (26.2) 0.01
  Emergency presentations or hospitalisation due to asthma
  ≥1 46 (12.3) 9 (8.7) 37 (13.7) 0.279
  Doctor visit due to asthma
  ≥1 267 (71.2) 65 (62.5) 202 (74.5) 0.01
*In the previous 12 months.
GINA, Global Initiative for Asthma-defined control.
than a third of SABA overusers and just under one-fifth 
of SABA non-overusers were administering five or more 
puffs of their SABA medication. This finding has signif-
icant implications for the way in which we ask about 
SABA use (ie, the determination of SABA overuse which 
is currently based on greater than two times per week 
alone), without considering the number of doses. If, in 
this study, SABA use was based on both occasion and 
dose, overuse of SABA would have been identified in 75% 
(308/412) of participants. This study was not powered to 
explore factors associated with such high doses of SABA 
use, however it raises questions about patient’s habitual 
copyright.
 o
n
 August 23, 2019 at University of Aberdeen. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-028995 on 14 August 2019. Downloaded from 
7Azzi EA, et al. BMJ Open 2019;9:e028995. doi:10.1136/bmjopen-2019-028995
Open access
Table 4 Preventer inhaler use overall and by short-acting beta agonist (SABA) overuse versus non-overuse (n=375)
Asthma preventermedication
n (%)
Overall
n=375
SABA overuse
No
n=104
Yes
n=271 P value
Preventer instruction
  Every day 214 (57.1) 43 (41.3) 171 (63.1) P<0.001
  As required 112 (29.9) 39 (37.5) 73 (26.9)
  Don’t know 49 (13.1) 22 (21.2) 27 (10)
Preventer adherence
  I take it everyday 99 (26.4) 21 (20.2) 78 (28.8) 0.322
  I take it some days but others I do not 88 (23.5) 20 (19.2) 68 (25.1)
  I used to take it but now I do not 32 (8.5) 7 (6.7) 25 (9.2)
  I take it only when I have symptoms 97 (25.9) 38 (36.5) 59 (21.7)
  I never take it 59 (15.7) 18 (17.3) 41 (15.1)
Reasons for non-adherence*
  Don’t need it 234 (62.4) 65 (62.5) 169 (62.4) 0.971
  Side effects experienced 68 (18.1) 12 (11.5) 56 (20.6) 0.04
  Don’t like it 23 (6.1) 4 (3.8) 19 (7) 0.140
  Doesn’t work 50 (13.3) 6 (5.8) 44 (16.2) 0.015
  Forget to take it 161 (43) 27 (26) 134 (49.4) <0.001
  Too expensive 16 (4.3) 4 (3.8) 12 (4.4) 0.916
*Participants were able to select multiple answers.
behaviours,30 the possibility of downregulation of beta 
receptors,31 increased bronchial hyper-responsiveness32 
or the severity of asthma exacerbations experienced.
The diagnosis of asthma remains a fundamental 
problem in many cohorts impacting on disease manage-
ment. Within this cohort of primary care patients, 1 in 
5 participants purchase an SABA medication without 
having an asthma diagnosis, and 1 in 8 do not believe they 
had asthma despite having a doctor diagnosis. Of partici-
pants without a doctor diagnosis of asthma, over half were 
overusing their SABA medication. Almost all participants 
in the study reported that SABA medication was recom-
mended by a doctor, irrespective of whether there was an 
asthma diagnosis. Further research is needed to elucidate 
why participants without an asthma diagnosis are using 
and being recommended SABA medication. Further 
exploration is required to ascertain whether patients are 
being recommended OTC SABA for undiagnosed asthma 
or an exacerbating comorbid condition,2 or is it the pres-
ence of confounding comorbidities, such as AR, that can 
worsen asthma symptoms?
The majority of participants in this study had symp-
toms that warranted SABA use. A significant proportion 
of participants reported visiting their doctor in the past 
12 months, most participants with asthma reported that 
they did not ‘currently’ have a preventer medication. 
This seems remarkable, as these people visit the doctor 
and are symptomatic, overuse SABA and yet do not have 
a preventer. Worldwide adherence to preventer therapy 
is suboptimal33 and while those who had been prescribed 
a preventer acknowledged that they had been advised to 
take it daily, only 1 in 5 did so, while continuing to use 
their SABA more than two times per week. An alarming 
factor regarding preventer adherence was related to the 
participants’ perception that the preventer medication 
‘doesn’t work.’ This was prevalent in half the partici-
pants who acknowledged that they were advised to take 
preventer medication every day. These findings are 
consistent with previous research reporting that patients 
want immediate relief from asthma symptoms34 and that 
they learn that rapid symptom relief is best achieved with 
SABA rather than preventer medication, which has no 
immediate perceived benefit. This study brings to light an 
interesting concept surrounding patient perceived effec-
tiveness of preventer therapy. Perhaps patient non-adher-
ence to preventer therapy may truly identify a cohort of 
patients in which, as they report, their preventer medi-
cation truly ‘does not work.’ Could it be that a subset of 
these patients are in fact those patients in whom inhaled 
corticosteroids (ICS) are not effective, that is, patients 
with asthma who have neutrophilic as opposed to eosin-
ophilic airway inflammation, or they simply perceive it 
non-effective due to non-adherence or incorrect inhaler 
technique. This could be explored further in the future, 
in particular as the question about asthma phenotypes 
continues to be a topic of great discussion at this time.
When considering the pattern of preventer use, 1 in 
4 participants reported that they only take preventer 
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therapy when they have symptoms, that is, as needed, 
regardless of the medication prescribed. This is contrary 
to current management guidelines, which highlights that 
even patients with mild symptoms will benefit from daily 
ICS treatment. Once again, this highlights that a signif-
icant proportion of asthma morbidity and its associated 
costs in Australia are preventable.7
When it came to the asthma status of participants, 
a high proportion reported symptoms consistent with 
partially or uncontrolled asthma. This finding is consis-
tent with findings from a number of multinational, inter-
national and local studies.6 7 24 26 While participants of 
this study were recruited at the time of SABA request 
in the pharmacy, which may suggest they were currently 
experiencing symptoms/a flare-up, this is nevertheless 
an unacceptably high proportion of people with asthma 
who had poorly controlled disease. This is concerning, 
particularly in a developed country with an abundance of 
medical services and healthcare accessibility. In trying to 
determine the asthma severity of the participants in this 
study, it was noted that about a quarter of participants 
reported taking at least one dose of oral corticosteroids 
in the last 12 months to treat an acute exacerbation. 
This figure is lower than that identified in international 
data sets; where 44% of respondents in Europe reported 
having used oral steroids6 and 77% in Asia25 where SABA 
is available on prescription only, however it is consistent 
with Australian research.24 One possible reason for this 
finding is an under-reporting of oral corticosteroids use 
in this cohort, however there is another possible explana-
tion. What this finding potentially suggests is that perhaps 
the population visiting community pharmacy in Australia, 
to purchase OTC SABA, may be a population with milder 
asthma overall, though still symptomatic. There are insuf-
ficient data surrounding the treatment of patients with 
mild asthma due to their variability of symptoms. This 
potentially places community pharmacists in a unique 
position to be able to identify patients, with milder 
disease, who are experiencing poor control and not using 
preventer medication, by adopting the paradigm of treat-
able traits35 that can be identified in a pharmacy setting. 
We suggest that this be taken one step further, where 
pharmacists can begin to identify treatable factors that 
warrant oral steroid use and SABA overuse.
In exploring this population, it is important to consider 
comorbidities, which may trigger poor asthma control 
and potentially lead to the overuse of SABA. The most 
common comorbidity among participants in this study 
was AR, which was experienced to a moderate-severe 
extent and reported to be burdensome to day-to-day 
living, especially among SABA overusers. While a majority 
of participants recognised that they had AR, either as a 
result of doctor diagnosis or self-diagnosis, 1 in 10 expe-
rienced symptoms that were suggestive of AR yet did not 
recognise them as such. As with recent global research in 
AR,24 this study once again highlights the high burden of 
AR on individuals (whether diagnosed or not) and as in 
this study, on individuals with asthma and having poorly 
controlled disease.36 37 This study identifies the gap in AR 
management in the community24 and an opportunity for 
pharmacists to engage with patients around optimising 
AR control.
In addition to AR, a significant proportion of partici-
pants also reported having gastro-oesophageal reflux 
disease, cardiovascular disease and depression. In recent 
research these comorbidities have been identified as treat-
able traits.10 It is known that extrapulmonary traits can 
either exacerbate asthma or mimic symptoms of asthma, 
making it essential for HCPs to rule out any poorly 
controlled conditions and ensure they are adequately 
managed and that asthma control is achieved and main-
tained. There is evidence suggesting that focusing on 
treatable traits can lead to improvements in patients’ 
quality of life, and allow for the engagement of patients 
in a multidimensional management plan.38 Participants 
with coexisting chronic obstructive pulmonary disease 
(COPD) are an interesting cohort, as 1 in 10 participants 
reported coexisting COPD and almost all overused their 
SABA medication, suggesting that a review of their respi-
ratory status and treatment is required.
This study uncovered several inconsistencies, misunder-
standings and disconnects between participant responses 
as they related to medication use, asthma control and 
asthma diagnosis. While it is not possible to definitely 
determine the causes of SABA overuse in this cohort, 
there are several possible explanations which need to be 
considered. Research suggests that patients under-report 
their symptoms, commonly due to their lack of percep-
tion in regard to actual level of asthma control.6 24 25 
That is, patients may tolerate their symptoms and deem 
them to be the ‘norm’ or perhaps they manage their 
asthma with a ‘crisis-orientated’ approach, that is, they 
only respond to symptoms when they are bad.6 25 There-
fore, it is possible in this survey that participants may 
be over-reporting or under-reporting of symptoms and 
medication use, due to patient-related factors. Partici-
pants reported differing answers when asked about medi-
cation use and adherence to preventer therapy. In this 
study we were unable to ascertain how many participants 
were prescribed and dispensed a preventer medication 
to elucidate their actual adherence. Participants were 
asked a series of questions relating to current ‘owner-
ship’ of a preventer (‘Do you currently have a preventer…?’), 
instruction on preventer use (‘How often does your doctor 
want you to take your preventer?’) and how participants take 
their preventer. This uncovered interesting/inconsistent 
results with a higher proportion of participants reporting 
receiving instruction on how to use a preventer than those 
reporting that they currently had a preventer. This could 
be interpreted in at least two ways: some participants 
were prescribed a preventer but did not currently have 
one, or there was a misinterpretation of the later ques-
tion relating to ‘How often does the doctor want you to take 
this (preventer) medication?’. The lack of clarity with regard 
to the appropriateness of the instruction received by the 
doctor and its correlation with adherence is a limitation 
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of this line of questioning. Participant responses further 
varied when asked SABA use (>2 occasions per week over 
the last 4 weeks). We speculate that participants prefer to 
give socially desirable answers and this is consistent with 
past research.39 This raises the question—due to incon-
sistencies within research data that our old approach of 
simply asking about asthma and asthma medication usage 
is problematic and control in these patients is not being 
achieved.35 Future research is required to determine the 
extent of symptom-driven SABA use and distinguished 
from SABA use associated with exercise or due to HCP 
instruction. This is a limitation within this study as SABA 
overuse classification could not accurately factor in if the 
use was for symptoms and/or exercise, future studies will 
need to explore this. This raises the question surrounding 
clinician-used terminology; whether it be understood or 
correctly interpreted by the patient. Research is needed 
to find patient-suited terminology to enable effective, 
efficient and appropriate assessment and treatment of 
asthma and to deter the provision of socially desirable 
responses. Our approach in addressing asthma requires 
change and a multidisciplinary approach for phenotype 
treatment moving towards individualised patient treat-
ment and care in a real-life setting.
While SABA medication is not available OTC in 
many countries, this research has global implications, 
healthcare relevance and should not be discounted as 
country specific. It identifies patient-driven medication 
purchasing and taking decisions and patterns of medi-
cation use/misuse. Globally, patients present to pharma-
cies to purchase medications of their ‘choosing’.40 In this 
study, while 68% of patients report that they currently 
have a preventer medication, only 26% report taking it 
every day. While there is no direct comparative evidence 
with Australia, there is evidence to suggest that Austra-
lians with asthma may not be dissimilar to people with 
asthma globally when it comes to their perceptions of 
their disease, in fact there is growing global evidence 
that people with asthma all around the world exhibit key 
similarities in terms of disease control and perceptions 
of their asthma.7 9 25 26 39 41 The correlation between ICS 
adherence and the availability of SABA OTC is unknown, 
hence further research is necessary to determine whether 
the availability of OTC SABA could potentially exacer-
bate poor ICS adherence (ie, patient runs out of their 
preventer and chooses to get a reliever OTC only perhaps 
as a matter of convenience). In pharmacy this is a missed 
opportunity to rectify and begin to address this issue of 
patient medication choice leading to preventer underuse 
and SABA overuse. While most patients visit other HCPs 
such as physicians, it is clearly not enough to just maintain 
what is currently being done, as asthma control world-
wide is suboptimal. We need to take a multidisciplinary 
approach and engage physicians and prescribers, and 
pharmacists, so that problems are identified at all health-
care levels and any point that patients seek treatment.
This study recruited participants in real time, making it 
a major strength of this study, data were collected in real 
time from a real-life cohort of SABA users, which is broad 
in nature and reach, using validated tools to provide a 
complete picture of SABA medication use in the commu-
nity. This study explored factors surrounding partici-
pants’ purchase and use of SABA medications; however, it 
is limited by the fact that doctor confirmation of asthma 
diagnosis could not be established. A further potential 
limitation is the potential for selection bias in the recruit-
ment of this convenience sample. Due to the data being 
collected during pharmacy opening times, response rate 
was not captured and is unknown adding to the conve-
nience sample bias. While the study was run over a whole 
year, we are unable to discount that seasonality could be 
a major factor in SABA overuse, this should be explored 
in future studies. SABA pharmacy purchases could poten-
tially overidentify overuse of participants due to wors-
ening symptoms on that particular day or week further 
adding to selection bias, longitudinal data collection is 
necessary to identify consistent SABA overusers.
In conclusion, this is the first research to explore the 
real-life use of SABA in the community pharmacy, giving 
insights into individuals who overuse SABA medications 
and those who do not. This study uncovered a hidden 
population who can only be uncovered in community 
pharmacy; a cohort with suboptimal asthma, coexisting 
AR, poor ICS adherence and, in some cases, no asthma 
diagnosis. This research uncovered major disconnects 
in the thinking and behaviour of people with asthma. 
It highlights the need to better understand people 
with asthma and better use the opportunity provided 
through the community pharmacy to identify treatable 
traits, patients at risk of poorly controlled disease, and to 
address the issues of medication management. Perhaps 
the most significant finding of this research is that it 
identified people with asthma in the community who 
have poorly controlled asthma and without pharmacist’s 
intervention, may never be identified as problematic 
and in need of ICS treatment. We can no longer ignore 
the critical contribution that pharmacists have to iden-
tify problematic traits linked with poor medication use. 
This reinforces the importance of a multidisciplinary 
approach, and therefore the need for a collective effort 
to identify and treat these patients. Future research is 
needed to explore how the community pharmacist can 
better identify uncontrolled patients and to develop 
tools/strategies designed for community pharmacy to 
help identify these patients.
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